Oppenheimer Asset Management Inc. Has $1.40 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Oppenheimer Asset Management Inc. grew its stake in shares of argenx SE (NASDAQ:ARGX) by 11.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 3,255 shares of the company’s stock after acquiring an additional 339 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in argenx were worth $1,400,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. lifted its stake in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares in the last quarter. J.Safra Asset Management Corp raised its holdings in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the period. GAMMA Investing LLC lifted its position in shares of argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after acquiring an additional 63 shares in the last quarter. Mather Group LLC. acquired a new position in argenx in the 1st quarter worth approximately $38,000. Finally, Lindbrook Capital LLC grew its position in argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after purchasing an additional 37 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

ARGX has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised argenx from a “hold” rating to a “buy” rating in a research report on Thursday, July 25th. Truist Financial lifted their target price on argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Bank of America reiterated a “buy” rating and issued a $607.00 target price (up previously from $535.00) on shares of argenx in a report on Monday, June 24th. Wedbush raised their price target on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Finally, HC Wainwright upped their price objective on shares of argenx from $504.00 to $533.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average price target of $547.74.

argenx Stock Performance

ARGX opened at $529.06 on Thursday. The company has a market cap of $31.44 billion, a PE ratio of -93.47 and a beta of 0.62. The stock has a 50-day moving average of $508.53 and a 200-day moving average of $430.04. argenx SE has a 52-week low of $327.73 and a 52-week high of $554.74.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. The firm had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same quarter in the prior year, the business earned ($1.69) earnings per share. On average, research analysts predict that argenx SE will post -0.37 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.